Correct Answer: D. Acute hepatitis B
Acute hepatitis B is definitively diagnosed by the presence of HBsAg (positive) and anti-HBc IgM (positive). The IgM antibody to hepatitis B core antigen is the gold standard marker of acute HBV infection, appearing within the first 1–2 weeks of symptom onset and persisting for 6 months. HBsAg positivity indicates active viral replication. The negative anti-HBs rules out recovery or immunity (which would show anti-HBs without HBsAg). The clinical presentation of fever, jaundice, and malaise in the context of this serological pattern is pathognomonic for acute hepatitis B. In India, where HBV is endemic (particularly in certain regions and among healthcare workers), acute hepatitis B typically presents with fulminant hepatitis in 1–2% of cases, while most patients recover spontaneously. The absence of anti-HCV antibodies excludes hepatitis C. This serological window—HBsAg+ with anti-HBc IgM+—is the earliest and most specific indicator of acute HBV infection before seroconversion to anti-HBs occurs.
Why the other options are wrong
A. Acute hepatitis C — Hepatitis C serology is explicitly negative (anti-HCV antibodies: negative). Additionally, anti-HCV IgM would be expected in acute HCV, not anti-HBc IgM. HCV does not produce HBsAg or anti-HBc. This is a straightforward exclusion by negative HCV serology, but the trap is that students may confuse acute viral hepatitis presentations without carefully reading the serological panel. B. Chronic hepatitis C — Anti-HCV antibodies are negative, ruling out both acute and chronic hepatitis C. Chronic HCV would show anti-HCV positivity (often with HCV RNA detectable). The presence of HBsAg and anti-HBc IgM is entirely inconsistent with hepatitis C infection. This option is a distractor for students who may not carefully differentiate HBV from HCV serology. C. Chronic hepatitis B — Chronic hepatitis B is characterized by HBsAg positivity persisting >6 months, but anti-HBc IgM is negative or very low; instead, anti-HBc IgG is positive. The presence of anti-HBc IgM is the discriminating marker of acute infection. Chronic carriers may have normal or mildly elevated transaminases and lack the acute systemic symptoms described. This is the key NBE trap: students may see HBsAg+ and jump to chronic hepatitis B without recognizing that IgM positivity mandates acute infection.
High-Yield Facts
- Anti-HBc IgM is the earliest and most specific marker of acute hepatitis B, appearing within 1–2 weeks of symptom onset and persisting for ~6 months.
- HBsAg+ with anti-HBc IgM+ and anti-HBs− is the diagnostic triad of acute hepatitis B; anti-HBs appears only after recovery (window period).
- Chronic hepatitis B is defined by HBsAg persistence >6 months with anti-HBc IgG (not IgM) and typically negative or very low anti-HBc IgM.
- In India, acute hepatitis B accounts for ~5–10% of acute viral hepatitis cases; fulminant hepatic failure occurs in 1–2% of acute HBV infections.
- Anti-HCV antibodies are the screening test for hepatitis C; their absence rules out both acute and chronic HCV regardless of HBV status.
Mnemonics
**IgM = Acute, IgG = Chronic (HBV Serology Rule) If anti-HBc IgM is positive → acute infection. If anti-HBc IgG is positive (without IgM) → chronic or past infection. Use this rule to instantly differentiate acute from chronic hepatitis B. HBsAg+ → Active Virus; Anti-HBs+ → Immunity** HBsAg (surface antigen) = virus present. Anti-HBs (surface antibody) = recovered or vaccinated. They are mutually exclusive in most scenarios; if both are negative, the patient is susceptible.
NBE Trap
NBE pairs acute presentation (fever, jaundice, malaise) with HBsAg positivity to lure students into choosing chronic hepatitis B without carefully noting the anti-HBc IgM positivity, which is the discriminating marker of acute infection. Students who skip the IgM detail will incorrectly select chronic hepatitis B.
Clinical Pearl
In Indian clinical practice, acute hepatitis B often presents with fulminant hepatitis in healthcare workers and blood-exposed individuals. The IgM anti-HBc test is routinely ordered in government hospitals and private labs across India as part of the hepatitis serology panel; its presence immediately triggers counseling on transmission prevention and monitoring for fulminant failure, whereas chronic HBV carriers are managed with antiviral therapy (tenofovir/entecavir per NACO guidelines) only if HBeAg+ or ALT elevated.
_Reference: Harrison Ch. 304 (Hepatitis B); KD Tripathi Ch. 57 (Antiviral Agents & Hepatitis); Robbins Ch. 18 (Liver & Biliary Tract)_